FSPKF (Fisher & Paykel Healthcare) ROCE % : 21.58% (As of Sep. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Fisher & Paykel Healthcare ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Fisher & Paykel Healthcare's annualized ROCE % for the quarter that ended in Sep. 2024 was 21.58%.

Fisher & Paykel Healthcare ROCE % Historical Data

The historical data trend for Fisher & Paykel Healthcare's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fisher & Paykel Healthcare ROCE % Chart

Fisher & Paykel Healthcare Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

33.22

56.03

28.97

17.12

13.19

Fisher & Paykel Healthcare Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
ROCE %	Get a 7-Day Free Trial															12.10	24.63	14.54	10.60	21.58

Fisher & Paykel Healthcare ROCE % Calculation

Fisher & Paykel Healthcare's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	154.44	/	( ( (1368.405 - 179.888)	+	(1387.895 - 234.185) )	/ 2 )
	=	154.44	/	( (1188.517	+	1153.71)	/ 2 )
	=	154.44	/	1171.1135
	=	13.19 %

Fisher & Paykel Healthcare's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Mar. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Mar. 2024 )		(Q: Sep. 2024 )
	=	262.974	/	( ( (1387.895 - 234.185)	+	(1515.495 - 232.047) )	/ 2 )
	=	262.974	/	( ( 1153.71	+	1283.448 )	/ 2 )
	=	262.974	/	1218.579
	=	21.58 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2024) EBIT data.

Fisher & Paykel Healthcare (OTCPK:FSPKF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Fisher & Paykel Healthcare ROCE % Related Terms

Thank you for viewing the detailed overview of Fisher & Paykel Healthcare's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Fisher & Paykel Healthcare Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Fisher & Paykel Healthcare Corp Ltd (OTCPK:FSPKF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

FPH:New Zealand FPLB:Germany FPLB:Germany FPH:Australia

Address

15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013

Website

https://www.fphcare.com

Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use humidifiers, masks and related consumables and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns 42% of its revenue in the US, 32% in Europe, 18% in Asia-Pacific and the remaining 8% in emerging markets. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand and Mexico and has a multichannel distribution model.